Oct 17, 2019
Pharmaceutical companies are focusing on the development of combination treatments for heavily pre-treated and refractory patient populations.
Despite advances in the renal cell carcinoma (RCC) therapy landscape, the majority of patients with RCC will eventually develop resistance to available therapies and the disease will progress through several stages, requiring further lines of treatment.